This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Medidata Reports Record First Quarter 2014 Results

Stocks in this article: MDSO

Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced its financial results for the first quarter of 2014.

"Interest in Medidata’s platform is at an all-time high as our clients and prospects look to transform clinical development,” said Tarek Sherif, Medidata's chairman and chief executive officer. “We are seeing great sales momentum, as our pipeline continues to build, giving us confidence that 2014 will be another outstanding year. Our industry focus, along with our ability to execute, innovate and make targeted strategic investments, is driving competitive advantage while laying the foundation for sustainable long-term success. Deep client relationships, client wins and strengthening partnerships with CROs and systems integrators are solidifying our leadership position in the global clinical research ecosystem.”

First Quarter 2014 Results

  • Total revenues for the first quarter of 2014 were $76.6 million, an increase of $13.3 million, or 21%, compared with $63.3 million in 2013. Subscription revenue was $63.8 million, an increase of 26% compared with the same period last year.
  • GAAP operating income for the quarter was $0.3 million, compared with $7.1 million in the first quarter of 2013. Non-GAAP operating income* for the first quarter of 2014 was $12.5 million, compared with $14.2 million a year ago.
  • GAAP net (loss) for the first quarter of 2014 was ($1.8) million, or ($0.03) per diluted share, compared with net income of $5.7 million, or $0.11 per diluted share, in the first quarter of 2013. Adjusted non-GAAP net income* for the first quarter of 2014 was $5.9 million, or $0.11 per diluted share, compared with $9.1 million, or $0.17 per diluted share, in the first quarter of 2013. See the non-GAAP reconciliation included in this release for full details of the non-GAAP adjustments.
  • Total cash, cash equivalents and marketable securities were $403.5 million at the end of the first quarter of 2014, an increase of $279.5 million, or 225%, compared with $124.0 million at the end of the first quarter of 2013, primarily due to net proceeds from the convertible senior notes issued during 2013 and strong cash flows over the past year.
  • Cash flow from operations was ($6.3) million in the first quarter of 2014, compared with $2.9 million a year ago.

Additional Highlights

  • Medidata’s customer base grew to 420, with 32 new clients added in the first quarter of 2014, an increase of 88% over the number of new clients added in the first quarter of 2013. Customer growth was realized in all regions and across multiple products.
  • 52% of customers had committed to multiple products at the end of the first quarter of 2014, up from 41% at the end of the first quarter of 2013.
  • Medidata’s industry-leading CRO program continued to grow, with three new partners added, including a top 5 CRO. Several partners also began using a broader set of applications within the Medidata Clinical Cloud™, including Medidata’s trial management solution for their own work.
  • Billings were $90 million in the first quarter of 2014, a 43% increase over the first quarter of 2013.
  • Subscription backlog for the remainder of the year as of March 31, 2014 increased to $177 million, an increase of $21 million year over year. Subscription backlog does not include revenues associated with intra-year renewals. Including a minimum of $15 million of revenue associated with remaining intra-year renewals, subscription backlog would have increased to $192 million.
  • Medidata's overall revenue retention rate was nearly 100%.

"We are off to a good start to the year and on track to achieving the financial outlook we provided earlier in the year,” said Cory Douglas, Medidata’s chief financial officer. “We continue to make disciplined investments to maximize our long-term opportunity to drive platform adoption while advancing our growth trajectory.”

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,759.48 +298.16 1.81%
S&P 500 1,960.79 +33.68 1.75%
NASDAQ 4,473.36 +90.5130 2.07%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs